What caused the large pre-market move in TMD.TO stock?

The pre-market surge appears driven by speculative volume and renewed interest in Titan’s Enos robotic program. No major corporate press release matched the spike; coverage on MarketBeat increased attention. Thin prior liquidity amplified the percentage move.

How does Meyka rate TMD.TO stock and what does that mean?

Meyka AI rates TMD.TO with a score out of 100: Score 64.50, Grade B, Suggestion HOLD. The grade factors benchmark comparison, sector performance, growth, metrics, and analyst signals. It is informational, not investment advice.

What are the key financial risks for TMD.TO stock?

Key risks include negative EPS (**-1.73**), limited revenue scale, small workforce, and reliance on future commercialization of the Enos system. High volatility and low institutional coverage raise execution risk for large trades.

What price target does Meyka forecast for TMD.TO stock?

Meyka AI's forecast model projects a 12-month baseline of **C$1.50**, a conservative **C$0.60**, and an aggressive **C$2.50**. These are model outputs and not guaranteed outcomes.

CA Stocks

TMD.TO Titan Medical Inc. (TSX) jumps 2149.99% pre-market: watch liquidity surge

ByHuzaifa Zahoor January 21, 2026

TMD.TO stock surged in pre-market trading on 21 Jan 2026, jumping to C$1.13 from C$0.05, a 2149.99% intraday move on 117,220 shares. The spike pushed the day high to C$1.13 and lifted market cap to about C$128.30M on the TSX in Canada. Heavy volume and a large gap from the previous close highlight short-term liquidity and volatility, prompting traders to reassess risk and reward for Titan Medical Inc. (TMD.TO).